Endometrial clear cell adenocarcinoma

Summary

Endometrial clear cell adenocarcinoma (MONDO:0006191) is a disease and 39 clinical trials. Top therapeutic interventions include cisplatin, cabozantinib, and metformin. A subtype of clear cell adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 39

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	endometrial clear cell adenocarcinoma
Mondo ID	MONDO:0006191
EFO	EFO:1000231
DOID	DOID:5299
ICD-11	388735319
NCIT	C8028
UMLS	C0279765
MedGen	124655
Anatomy (UBERON)	UBERON:0001295
Is cancer (heuristic)	no

Also known as: clear cell carcinoma of endometrium · clear cell carcinoma of the endometrium · endometrial clear cell adenocarcinoma · endometrium clear cell adenocarcinoma

Data availability: 8 cell lines.

Disease family

This is a subtype of clear cell adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › clear cell adenocarcinoma › endometrial clear cell adenocarcinoma

Related subtypes (10): hepatocellular clear cell carcinoma, fallopian tube clear cell adenocarcinoma, bladder clear cell adenocarcinoma, urethra clear cell adenocarcinoma, glycogen-rich clear cell breast carcinoma, extrahepatic bile duct clear cell adenocarcinoma, clear cell renal carcinoma, ovarian clear cell adenocarcinoma, cervical clear cell adenocarcinoma, hidradenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 39.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	17
PHASE1	10
PHASE3	7
Not specified	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03422198	PHASE3	RECRUITING	Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
NCT03914612	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT05256225	PHASE3	RECRUITING	Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT00006011	PHASE3	COMPLETED	Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00807768	PHASE3	UNKNOWN	Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
NCT00942357	PHASE3	UNKNOWN	Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
NCT02065687	PHASE2/PHASE3	UNKNOWN	Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
NCT02501954	PHASE3	COMPLETED	Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
NCT00977574	PHASE2	ACTIVE_NOT_RECRUITING	Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT04719273	PHASE2	ACTIVE_NOT_RECRUITING	Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
NCT05112601	PHASE2	RECRUITING	Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT00492778	PHASE2	UNKNOWN	Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
NCT00820898	PHASE2	COMPLETED	Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00888173	PHASE2	COMPLETED	Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01005329	PHASE2	COMPLETED	Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
NCT01011933	PHASE2	COMPLETED	Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01132820	PHASE2	COMPLETED	Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01210222	PHASE2	COMPLETED	Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT01225887	PHASE2	COMPLETED	Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01307631	PHASE2	COMPLETED	Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
NCT01642082	PHASE2	COMPLETED	Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01935934	PHASE2	COMPLETED	Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
NCT02059265	PHASE2	TERMINATED	Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
NCT02874430	PHASE2	TERMINATED	Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
NCT03836157	PHASE2	WITHDRAWN	Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
NCT05001282	PHASE1/PHASE2	TERMINATED	A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
NCT02142803	PHASE1	ACTIVE_NOT_RECRUITING	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
NCT03120624	PHASE1	ACTIVE_NOT_RECRUITING	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
NCT05950464	PHASE1	RECRUITING	Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT00005830	PHASE1	COMPLETED	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00005840	PHASE1	COMPLETED	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00575952	PHASE1	COMPLETED	Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
NCT01440998	PHASE1	COMPLETED	Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
NCT01935973	PHASE1	COMPLETED	Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT02020707	PHASE1	COMPLETED	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
NCT05498597	PHASE1	UNKNOWN	AMT-151 in Patients With Selected Advanced Solid Tumours
NCT04906382	EARLY_PHASE1	TERMINATED	Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
NCT01737619	Not specified	ACTIVE_NOT_RECRUITING	PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer
NCT05049538	Not specified	RECRUITING	Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	8
CABOZANTINIB	4	3
METFORMIN	4	2
FILGRASTIM	4	1
HYALURONIDASE (HUMAN RECOMBINANT)	4	1
IXABEPILONE	4	1
MIRVETUXIMAB SORAVTANSINE	4	1
NINTEDANIB	4	1
PACLITAXEL	4	1
PEGFILGRASTIM	4	1
PEMBROLIZUMAB	4	1
PERTUZUMAB	4	1
RUXOLITINIB	4	1
SELUMETINIB	4	1
SODIUM PERTECHNETATE TC 99M	4	1
TEMSIROLIMUS	4	1
BRIVANIB ALANINATE	3	1
CEDIRANIB MALEATE	3	1
DALANTERCEPT	3	1
TREBANANIB	3	1
ONAPRISTONE	2	1
SAPANISERTIB	2	1
UPROSERTIB	2	1
ZENIDOLOL	2	1
PASIFOLATE EXATECAN	1	1
CHEMBL48	0	1
CHEMBL4463209	0	1
CHEMBL3962632	0	1
CHEMBL3991933	0	1